Smith Chas P & Associates Pa Cpas Amgen Inc Transaction History

Smith Chas P & Associates Pa Cpas

$1.65 Billion
Q1 2024

A detailed history of Smith Chas P & Associates Pa Cpas transactions in Amgen Inc stock. As of the latest transaction made, Smith Chas P & Associates Pa Cpas holds 111,994 shares of AMGN stock, worth $35 Million. This represents 1.93% of its overall portfolio holdings.

Number of Shares

111,994

Previous 108,838 2.9%

Holding current value

$35 Million

Previous $31.3 Million 1.58%

% of portfolio

1.93%

Previous 2.07%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	BUY	$268.87 - $324.56 $848,553 - $1.02 Million	3,156 Added 2.9%	111,994 $31.8 Million
Q4 2023 Feb 01, 2024	BUY	$255.7 - $288.46 $734,626 - $828,745	2,873 Added 2.71%	108,838 $31.3 Million
Q3 2023 Nov 02, 2023	BUY	$218.65 - $271.46 $1.86 Million - $2.31 Million	8,507 Added 8.73%	105,965 $28.5 Million
Q2 2023 Jul 31, 2023	BUY	$214.27 - $253.37 $20.6 Million - $24.4 Million	96,207 Added 7690.41%	97,458 $21.6 Million
Q1 2023 Apr 27, 2023	SELL	$225.79 - $275.2 $11,515 - $14,035	-51 Reduced 3.92%	1,251 $303,000

Q4 2022 Jan 12, 2023	SELL	$229.03 - $291.01 $132,608 - $168,494	-579 Reduced 30.78%	1,302 $342,000
Q3 2022 Nov 22, 2022	BUY	$224.46 - $253.15 $33,669 - $37,972	150 Added 8.67%	1,881 $424,000
Q2 2022 Jul 15, 2022	BUY	$230.71 - $256.74 $10,151 - $11,296	44 Added 2.61%	1,731 $421,000
Q1 2022 May 12, 2022	BUY	$219.27 - $242.57 $127,176 - $140,690	580 Added 52.39%	1,687 $408,000
Q4 2021 Feb 07, 2022	SELL	$198.88 - $227.6 $114,157 - $130,642	-574 Reduced 34.15%	1,107 $249,000
Q3 2021 Oct 12, 2021	BUY	$212.27 - $248.7 $849 - $994	4 Added 0.24%	1,681 $358,000
Q4 2020 Feb 10, 2021	BUY	$216.38 - $257.67 $2,380 - $2,834	11 Added 0.66%	1,677 $386,000
Q2 2020 Aug 13, 2020	BUY	$197.81 - $242.74 $18,791 - $23,060	95 Added 6.05%	1,666 $393,000
Q1 2020 May 11, 2020	BUY	$182.24 - $241.7 $14,761 - $19,577	81 Added 5.44%	1,571 $319,000
Q4 2019 Feb 04, 2020	SELL	$189.21 - $243.2 $756 - $972	-4 Reduced 0.27%	1,490 $359,000
Q3 2019 Nov 06, 2019	BUY	$174.11 - $208.62 $696 - $834	4 Added 0.27%	1,494 $289,000
Q2 2019 Aug 09, 2019	BUY	$166.7 - $195.41 $18,503 - $21,690	111 Added 8.05%	1,490 $275,000
Q1 2019 May 08, 2019	BUY	$180.87 - $203.88 $18,087 - $20,388	100 Added 7.82%	1,379 $262,000
Q3 2018 Nov 09, 2018	SELL	$185.29 - $208.89 $37,058 - $41,778	-200 Reduced 13.52%	1,279 $265,000
Q2 2018 Aug 03, 2018	SELL	$166.05 - $186.51 $1,328 - $1,492	-8 Reduced 0.54%	1,479 $273,000
Q4 2017 Feb 09, 2018	SELL	$168.79 - $188.59 $2,194 - $2,451	-13 Reduced 0.87%	1,487 $259,000
Q3 2017 Oct 31, 2017	BUY	$167.29 - $191.0 $250,935 - $286,500	1,500	1,500 $280,000

Others Institutions Holding AMGN

# of Institutions

2,930

Shares Held

401M

Call Options Held

6.59M

Put Options Held

6.6M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $167B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith Chas P & Associates Pa Cpas, based on Form 13F filings with the SEC.

News

Stay updated on Smith Chas P & Associates Pa Cpas with notifications on news.

Account

Smith Chas P & Associates Pa Cpas Amgen Inc Transaction History